Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.
J Allergy Clin Immunol
; 146(1): 213-215, 2020 Jul.
Article
in En
| MEDLINE
| ID: mdl-32437739
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Antirheumatic Agents
/
Interleukin 1 Receptor Antagonist Protein
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Allergy Clin Immunol
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: